Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | ABHD6 | Q9BV23 | 4/20 | 0.35 |
| ▸ | CNR1 | P21554 | 3/20 | 0.33 |
| ▸ | CTSL | P07711 | 2/20 | 0.33 |
| ▸ | CTSB | P07858 | 2/20 | 0.33 |
| ▸ | CTSS | P25774 | 2/20 | 0.33 |
| ▸ | CTSK | P43235 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | LDHA | P00338 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6090567 | 1.00 | CYP1A2 (0.37) | CYP1A2ABHD6CNR1CTSLCTSB | |
| SCHEMBL20246079 | 0.72 | CYP1A2 (0.34) | CYP1A2CTSLCTSBCTSSCTSK | |
| SCHEMBL24901136 | 0.70 | HTR2A (0.36) | ABHD6 | |
| SCHEMBL16098573 | 0.69 | CA2 (0.37) | CTSLCTSBCTSSCTSKLDHA | |
| SCHEMBL23559281 | 0.69 | FFAR1 (0.36) | — | |
| SCHEMBL8538472 | 0.68 | ELANE (0.44) | LDHA | |
| SCHEMBL24945943 | 0.68 | POLB (0.39) | — | |
| SCHEMBL27801809 | 0.67 | POLB (0.41) | — | |
| SCHEMBL12490983 | 0.66 | ESR1 (0.46) | CYP1A2CYP2C19 | |
| SCHEMBL12273874 | 0.66 | ESR1 (0.46) | CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060287402-A1 | Cathepsin inhibitors | MERCK FROSST CANADA & CO. (CA) | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287402-A1 | Cathepsin inhibitors | CTSB, CTSK, CTSS | CYP1A2 2819/4885ABHD6 4515/4885CNR1 1004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.